JP Morgan Maintains Overweight on Insulet, Lowers Price Target to $275

Benzinga Newsdesk www.benzinga.com Negative 93.1%

Neg 93.1% Neu 0% Pos 0%

JP Morgan analyst Robbie Marcus maintains Insulet (NASDAQ:PODD) with a Overweight and lowers the price target from $340 to $275.